<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082679</url>
  </required_header>
  <id_info>
    <org_study_id>H-2008-0242</org_study_id>
    <nct_id>NCT01082679</nct_id>
  </id_info>
  <brief_title>Treatment for Opioid Dependent Offenders</brief_title>
  <official_title>Treatment for Opioid Dependent Offenders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Wisconsin, Milwaukee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is examining the feasibility of a primary care and a specialist treatment&#xD;
      (methadone clinic) model of treatment for 15 offenders who are part of two community&#xD;
      supervision programs: Drug Court and the Treatment Alternative Program (TAP) in Dane County.&#xD;
      The questions addressed by future larger studies based upon the current pilot-feasibility&#xD;
      study will center around whether access to primary health care as opposed to more traditional&#xD;
      methadone treatment services will improve the health and criminal justice outcomes for&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention rate of participants in the study</measure>
    <time_frame>12 months</time_frame>
    <description>This study is focused on Dane County Drug Treatment Court and Treatment Alternative Program participants.&#xD;
The study will determine feasibility of monitoring participants in primary care as opposed to the usual standard of specialty care.&#xD;
Feasibility of monitoring participants will be studied in terms of retention rate of participants in the study</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>methadone via specialty care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboxone via specialty care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Suboxone via primary care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <description>daily for 12 months</description>
    <arm_group_label>methadone via specialty care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine (Suboxone)</intervention_name>
    <description>daily for 12 months</description>
    <arm_group_label>Suboxone via primary care</arm_group_label>
    <arm_group_label>Suboxone via specialty care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of opioid dependence&#xD;
&#xD;
          -  opioid positive urine drug screen&#xD;
&#xD;
          -  participation in local Drug Treatment Court or Treatment Alternative Program&#xD;
&#xD;
          -  women of childbearing potential who have a negative screening urine pregnancy test and&#xD;
             are willing to use appropriate birth control methods during the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current alcohol or sedative dependence&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  women who are currently breast-feeding&#xD;
&#xD;
          -  complex psychiatric co-morbidity (e.g. suicidality, psychosis)&#xD;
&#xD;
          -  complex medical co-morbidity (e.g. major cardiovascular, renal, or&#xD;
             gastrointestinal/hepatic disease)&#xD;
&#xD;
          -  current pharmacotherapy with an agent which is contraindicated in combination with&#xD;
             Suboxone or methadone according to drug labeling&#xD;
&#xD;
          -  paralytic ileus, coronary artery disease or heart arrhythmia, recent head injury,&#xD;
             obstructive sleep apnea, severe asthma or COPD, end-stage renal disease, or severe&#xD;
             morbid obesity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randy Brown, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin - Madison, Department of Family Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Brown R, Gassman M, Hetzel S, Berger L. Community-based treatment for opioid dependent offenders: a pilot study. Am J Addict. 2013 Sep-Oct;22(5):500-2. doi: 10.1111/j.1521-0391.2013.12049.x. Epub 2013 Apr 3.</citation>
    <PMID>23952897</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid dependent</keyword>
  <keyword>methadone</keyword>
  <keyword>Suboxone</keyword>
  <keyword>buprenorphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

